Sanofi, a France-based multinational pharmaceutical company, has agreed to produce Principia Biopharma's Bruton's tyrosine kinase inhibitor, PRN2246, it was reported on Friday.
The product is intended for the treatment of multiple sclerosis and possibly other central nervous system diseases.
The contract between the firms provides Sanofi with an exclusive, worldwide license to develop and commercialise PRN2246, which is presently in clinical development. According to the agreement, Principia will receive USD40m upfront payment, future milestone payments that are likely to cost USD765m and royalties on product sales.
The experimental oral treatment, PRN2246, has been designed to gain access to the brain and spinal cord by overcoming the blood-brain barrier and affecting immune cell and brain cell signalling. As per the deal, Principia has been given an option to co-fund phase three development of the product. This would be in exchange for increased royalties on global product sales or a profit and loss sharing arrangement in the US. According to the partners, the license transaction is likely to be completed in the fourth quarter of 2017, if it can clear customary regulatory approvals.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference